Ceribell, a Sunnyvale, California-based company that offers an online-linked, portable electroencephalogram (EEG), has raised $50 million in equity financing.
Ally Bridge Group led the event.
The company plans to utilize the funds to continue commercial expansion in emergency departments and intensive care units and to use machine learning and EEG access to treat other neurological issues that aren’t related to seizures.
Ceribell’s CEO Jane Chao, Ceribell deploys the cloud-linked, portable electroencephalogram (EEG) device to measure brain waves in a matter of minutes to determine the likelihood of seizures and other disorders in emergency rooms as well as ICUs. The system can be swiftly and effortlessly applied to patients by any healthcare professional and provides brain-monitoring results in just a few moments. Its Ceribell EEG System first received FDA 510(k) approval in 2017 and is now commercially sold within the United States. The company announced the receipt of Breakthrough Device Designation for its delirium indication from the United States Food and Drug Administration (FDA) at the beginning of this month.
